← Back to Screener
Staar Surgical Co (STAA)
Price$29.55
Value ScoreD
Growth ScoreC
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)-6.64%
Price vs S&P 500 (4W)4.96%
VGM Score50.39
Market Capitalization$1.49B
All Metrics
P/CF (Annual)57.84x
Book Value / Share (Quarterly)$7.08
P/TBV (Annual)3.74x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-5.57%
Cash Flow / Share (Quarterly)$-1.10
Price vs S&P 500 (YTD)18.52%
Gross Margin (TTM)76.89%
Net Profit Margin (TTM)-7.24%
EPS (TTM)$-0.43
10-Day Avg Trading Volume1.04M
EPS Excl Extra (TTM)$-0.43
Revenue Growth (5Y)7.93%
EPS (Annual)$-1.62
ROI (Annual)-23.37%
Gross Margin (Annual)76.19%
Net Profit Margin (5Y Avg)-1.83%
Cash / Share (Quarterly)$3.29
Revenue Growth QoQ (YoY)119.59%
ROA (Last FY)-17.81%
Revenue Growth TTM (YoY)4.03%
EBITD / Share (TTM)$-0.36
ROE (5Y Avg)-0.36%
Operating Margin (TTM)-9.07%
Cash Flow / Share (Annual)$-0.81
P/B Ratio4.23x
P/B Ratio (Quarterly)2.84x
Net Income / Employee (Annual)$-84,100
EV / Revenue (TTM)4.67x
Net Interest Coverage (TTM)11.43x
ROA (TTM)-4.68%
EPS Growth QoQ (YoY)-12.41%
EV / EBITDA (TTM)42.97x
EPS Incl Extra (Annual)$-1.62
Current Ratio (Annual)4.55x
Quick Ratio (Quarterly)4.11x
3-Month Avg Trading Volume1.26M
52-Week Price Return63.07%
EV / Free Cash Flow (Annual)57.39x
Revenue / Employee (TTM)$303,400
Tangible BV / Share (Quarterly)$6.39
P/S Ratio (Annual)6.22x
Asset Turnover (Annual)0.53x
52-Week High$35.87
Operating Margin (5Y Avg)-0.75%
EPS Excl Extra (Annual)$-1.62
CapEx CAGR (5Y)-7.08%
Tangible BV CAGR (5Y)14.46%
26-Week Price Return9.29%
Quick Ratio (Annual)3.54x
13-Week Price Return47.10%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)5.12x
Enterprise Value$1.36B
Revenue / Share Growth (5Y)7.24%
Asset Turnover (TTM)0.65x
Book Value / Share Growth (5Y)10.39%
Revenue / Employee (Annual)$250,200
Inventory Turnover (Annual)1.90x
Pretax Margin (Annual)-34.36%
Cash / Share (Annual)$3.80
3-Month Return Std Dev66.38%
Gross Margin (5Y Avg)77.38%
Net Income / Employee (TTM)$-22,000
EBITDA Interim CAGR (5Y)3.87%
ROE (Last FY)-23.37%
Net Interest Coverage (Annual)106.09x
EPS Basic Excl Extra (Annual)$-1.62
P/FCF (TTM)834.74x
Receivables Turnover (TTM)4.79x
EV / Free Cash Flow (TTM)261.09x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.43
Receivables Turnover (Annual)3.64x
ROI (TTM)-6.07%
P/S Ratio (TTM)5.13x
Pretax Margin (5Y Avg)0.56%
Revenue / Share (Annual)$4.83
Tangible BV / Share (Annual)$6.35
Forward P/E63.00x
Price vs S&P 500 (52W)34.86%
Year-to-Date Return29.45%
5-Day Price Return-7.95%
EPS Normalized (Annual)$-1.62
ROA (5Y Avg)-0.19%
Net Profit Margin (Annual)-33.60%
Month-to-Date Return13.39%
Cash Flow / Share (TTM)$0.50
EBITD / Share (Annual)$-1.75
Operating Margin (Annual)-38.30%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-0.36%
LT Debt / Equity (Quarterly)0.15x
EPS Basic Excl Extra (TTM)$-0.43
P/TBV (Quarterly)3.15x
P/B Ratio (Annual)3.41x
Inventory Turnover (TTM)1.37x
Pretax Margin (TTM)-6.74%
Book Value / Share (Annual)$6.97
Price vs S&P 500 (13W)37.35%
Beta1.24x
P/FCF (Annual)84.56x
Revenue / Share (TTM)$5.70
ROE (TTM)-6.07%
52-Week Low$15.59
vGradeD
gGradeC
mGradeB
vgmGradeC
Show chart for
Earnings Surprise History
Q1 260.23est. -0.07
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
2.60
2.63
3.47
3.53
Industry Peers — Ophthalmic Goods(8)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
STAAStaar Surgical Co | D | C | B | $29.55 |
| ALCAlcon Inc. Ordinary Shares | C | C | C | $65.70 |
| COOThe Cooper Companies, Inc. Common Stock | C | C | D | $60.19 |
| BLCOBausch + Lomb Corporation | B | C | C | $15.39 |
| WRBYWarby Parker Inc. | D | B | C | $24.38 |
| EYENational Vision Holdings, Inc. Common Stock | A | D | D | $16.08 |
| RXSTRxSight, Inc. Common Stock | B | C | F | $5.24 |
| LUCYInnovative Eyewear, Inc. Common Stock | B | A | D | $1.00 |
| LUCYWInnovative Eyewear, Inc. Series A Warrants 8/16/27 | — | — | D | $0.05 |
About
STAAR Surgical Co manufactures Implantable Collamer Lenses (ICL) and delivery systems for refractive eye surgery. The company derives nearly all revenue from ICL sales, which are used to correct myopia and other refractive errors. A substantial portion of revenues comes from international markets.